Mr John McQueen

  • Affiliate (Institute of Cancer Sciences)


List by: Type | Date

Jump to: 2021 | 2019 | 2018
Number of items: 5.


Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)


Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)


Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

This list was generated on Thu Sep 23 07:47:40 2021 BST.